Echo Therapeutics (OTCMKTS:ECTE) versus ENDRA Life Sciences (OTCMKTS:NDRA) Head to Head Comparison

Share on StockTwits

Echo Therapeutics (OTCMKTS:ECTE) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

17.2% of ENDRA Life Sciences shares are owned by institutional investors. 7.0% of Echo Therapeutics shares are owned by company insiders. Comparatively, 11.4% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Echo Therapeutics and ENDRA Life Sciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Echo Therapeutics N/A N/A N/A N/A N/A
ENDRA Life Sciences $10,000.00 928.20 -$9.80 million ($2.10) -0.67

Echo Therapeutics has higher earnings, but lower revenue than ENDRA Life Sciences.

Analyst Ratings

This is a summary of recent recommendations for Echo Therapeutics and ENDRA Life Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Echo Therapeutics 0 0 0 0 N/A
ENDRA Life Sciences 0 0 3 0 3.00

ENDRA Life Sciences has a consensus target price of $6.00, suggesting a potential upside of 328.57%. Given ENDRA Life Sciences’ higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Echo Therapeutics.

Profitability

This table compares Echo Therapeutics and ENDRA Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Echo Therapeutics N/A N/A N/A
ENDRA Life Sciences N/A -326.97% -233.06%

Volatility and Risk

Echo Therapeutics has a beta of 8.89, indicating that its share price is 789% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Summary

ENDRA Life Sciences beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.

Echo Therapeutics Company Profile

Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc. to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. In addition, it has a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell CGM to medical facilities and individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd to research, develop, manufacture, and use CGM in the People's Republic of China, Hong Kong, Macau, and Taiwan. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Profund Advisors LLC Has $1.20 Million Stock Holdings in Colgate-Palmolive
Profund Advisors LLC Has $1.20 Million Stock Holdings in Colgate-Palmolive
Profund Advisors LLC Boosts Holdings in HCP, Inc.
Profund Advisors LLC Boosts Holdings in HCP, Inc.
Profund Advisors LLC Grows Position in Aqua America Inc
Profund Advisors LLC Grows Position in Aqua America Inc
Morgan Stanley  Shares Bought by Profund Advisors LLC
Morgan Stanley Shares Bought by Profund Advisors LLC
Weyerhaeuser Co  Shares Bought by Profund Advisors LLC
Weyerhaeuser Co Shares Bought by Profund Advisors LLC
Scotia Capital Inc. Invests $996,000 in Monster Beverage Corp
Scotia Capital Inc. Invests $996,000 in Monster Beverage Corp


 
© 2006-2019 Zolmax.